TGFB1 and neoplasm: CCL19 has potent systemic antitumour responses in vivo (Figures 1 and 2); it enhances the frequency of T-cell subsets and DCs at the tumour sites (Table 1); it promotes type 1 cytokine and antiangiogenic chemokine release as well as a decline in the immunosuppressive cytokine TGF-β (Figures 3 and 4).